OverviewSuggest Edit

Harvard Bioscience is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. 

The Company sells its products to thousands of researchers through its full-line catalog (and various other specialty catalogs), its websites, and through distributors, including GE Healthcare, Thermo Fisher Scientific Inc., and VWR.

TypePublic
Founded1901
HQHolliston, MA, US
Websiteharvardbioscience.com
Employee Ratings2.7
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)505(-2%)
Job Openings5
Revenue (FY, 2020)$102.1 M(-12%)
Share Price (Nov 2021)$8.1(+5%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Harvard Bioscience

James Green

James Green

Chairman, President and Chief Executive Officer
Michael Rossi

Michael Rossi

Chief Financial Officer
Katherine A. Eade

Katherine A. Eade

Director
John Kennedy

John Kennedy

Director
Kenneth Olson

Kenneth Olson

Chief Operating Officer
Thomas W. Loewald

Thomas W. Loewald

Director
Show more

Harvard Bioscience Office Locations

Harvard Bioscience has offices in Holliston, Montréal and Les Ulis
Holliston, MA, US (HQ)
84 October Hill Rd
Montréal, CA
6010 Rue Vanden Abeele, Saint-Laurent
Les Ulis, FR
6 Avenue des Andes
Show all (4)

Harvard Bioscience Financials and Metrics

Harvard Bioscience Revenue

Harvard Bioscience's revenue was reported to be $102.1 m in FY, 2020
USD

Revenue (Q1, 2021)

27.0m

Gross profit (Q1, 2021)

15.4m

Gross profit margin (Q1, 2021), %

57.2%

Net income (Q1, 2021)

(669.0k)

EBIT (Q1, 2021)

(239.0k)

Market capitalization (12-Nov-2021)

315.9m

Closing stock price (12-Nov-2021)

8.1

Cash (31-Mar-2021)

5.8m

EV

362.8m
Harvard Bioscience's current market capitalization is $315.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

105.2m108.7m108.7m104.5m101.9m120.8m116.2m102.1m

Revenue growth, %

3%0%(4%)

Cost of goods sold

59.3m59.9m56.1m54.3m57.6m51.9m44.1m

Gross profit

49.3m48.7m48.4m47.6m63.2m64.3m58.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.7m5.7m8.2m8.3m8.3m

Accounts Receivable

17.5m16.2m21.5m20.7m17.8m

Prepaid Expenses

3.9m4.2m3.1m

Inventories

22.3m21.4m25.1m22.1m22.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.8m)2.4m(19.0m)(4.3m)(865.0k)(2.9m)(4.7m)(7.8m)

Depreciation and Amortization

3.9m3.8m4.6m4.3m3.8m2.4m7.7m1.9m

Inventories

(3.1m)(1.2m)1.2m(548.0k)2.6m3.3m413.0k

Accounts Payable

(41.0k)1.1m2.6m(2.4m)(918.0k)1.6m(2.0m)511.0k
USDQ2, 2013

Financial Leverage

1.4 x
Show all financial metrics

Harvard Bioscience Acquisitions / Subsidiaries

Company NameDateDeal Size
Data Sciences InternationalJanuary 22, 2018$70 m

Harvard Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Harvard Bioscience Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Harvard Bioscience Online and Social Media Presence

Embed Graph

Harvard Bioscience Company Culture

  • Overall Culture

    B

    73/100

  • CEO Rating

    A

    77/100

  • Compensation

    B

    77/100

Learn more on Comparably

Harvard Bioscience News and Updates

Harvard Bioscience Announces Second Quarter 2021 Financial Results

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

Harvard Bioscience Announces First Quarter 2021 Financial Results

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins

Harvard Bioscience Announces Fourth Quarter 2020 Financial Results

Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt

Harvard Bioscience Schedules Fourth Quarter 2020 Earnings Conference Call for March 10, 2021 at 8:00 AM ET

HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on March 10, 2021, and will hold a conference call to discuss the results on March 10, 2021 at 8:00 a.m…

Harvard Bioscience Announces New Credit Facility

HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 million credit facility (the “Refinancing”). Proceeds from the new facility will be used to retire existing d…

Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference. The virtual event will take place…
Show more

Harvard Bioscience Blogs

Harvard Bioscience Announces Third Quarter 2021 Financial Results

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 23% year-over-year as sales momentum continues Pre-clinical product revenue up 28% Cellular and Molecular Technologies (CMT) product revenue up 19% HOLLISTON, Mass., Nov.

Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET

Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET Content Import Mon, 07/19/2021 - 16:45 Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET Jul 19,2021 …

Harvard Bioscience Schedules First Quarter 2021 Earnings Conference Call for May 6, 2021 at 8:00 AM ET

Harvard Bioscience Schedules First Quarter 2021 Earnings Conference Call for May 6, 2021 at 8:00 AM ET Content Import Mon, 04/19/2021 - 16:55 Harvard Bioscience Schedules First Quarter 2021 Earnings Conference Call for May 6, 2021 at 8:00 AM ET Apr 19,2021 This rel…

Harvard Bioscience Announces Third Quarter 2020 Financial Results

Disciplined cost management, cash conservation actions drive increased year-over-year operating income and reduced net debt Operating margin up year-over-year on GAAP and adjusted basis Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening Generated positive

Harvard Bioscience Schedules Third Quarter 2020 Earnings Conference Call for November 5, 2020 at 8:00 AM ET

HOLLISTON, MA. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on November 5, 2020 , and will hold a conference call to discuss the results on November 5, 2020 at 8:00

Harvard Bioscience to Present at Singular Research Compelling Values Webinar

HOLLISTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15  p.m. ET.
Show more

Harvard Bioscience Frequently Asked Questions

  • When was Harvard Bioscience founded?

    Harvard Bioscience was founded in 1901.

  • Who are Harvard Bioscience key executives?

    Harvard Bioscience's key executives are James Green, Michael Rossi and Katherine A. Eade.

  • How many employees does Harvard Bioscience have?

    Harvard Bioscience has 505 employees.

  • What is Harvard Bioscience revenue?

    Latest Harvard Bioscience annual revenue is $102.1 m.

  • What is Harvard Bioscience revenue per employee?

    Latest Harvard Bioscience revenue per employee is $202.2 k.

  • Who are Harvard Bioscience competitors?

    Competitors of Harvard Bioscience include F1000 Research, Leica Microsystems and Elektrofi.

  • Where is Harvard Bioscience headquarters?

    Harvard Bioscience headquarters is located at 84 October Hill Rd, Holliston.

  • Where are Harvard Bioscience offices?

    Harvard Bioscience has offices in Holliston, Montréal and Les Ulis.

  • How many offices does Harvard Bioscience have?

    Harvard Bioscience has 4 offices.